ObjectivesTo describe the clinical and epidemiolgical features of patients with metastatic colon cancer treated with bevacizumab at the National Cancer Institute of Colombia (NCI). MethodsReview was undertaken on 38 clinical cases of patients diagnosed for metastatic colorectal cancer and treated at the NCI Oncology Clinic from 2010 to 2011. ResultsMedian patient age when treated with bevacizumab was 57 years; most frequent metastatic sites were the liver and peritoneum. Most commonly used chemotherapy regimen with bevacizumab included 5 fluoruracil/leucovorin and FOLFOX. Bevacizumab was generally well tolerated, with few adverse events reported; median survival rate for patients treated with bevacizumab was 17.5 months. ConclusionsAnalysis on this series of medical cases describes the general characteristics of patients treated at the NCI for metastatic colorrectal cancer whose favorable adherence to treatment with bevacizumab was linked to the low toxicity of diverse chemotherapy regimens used for metastatic colorectal cancer.